Interpreting PROSTOX Results
Risk stratification into HIGH and LOW-AVERAGE risks of late GU toxicity by PROSTOX can help physicians and their patients decide on the safest course of radiation treatment.1
The patient report will show both a binary result (whether a patient is at LOW-AVERAGE RISK of toxicity versus HIGH RISK) as well as a risk curve showing the patient’s precise risk relative to that of others who have been tested with known outcomes.
We will issue results approximately 5-7 days after receiving a patient’s sample. The treating or ordering physician will receive an email link to access the report in the physician portal.
PROSTOX Ultra
Patients with a HIGH RISK result are ~7 times more likely to develop late grade ≥ 2 genitourinary toxicity compared to those with a LOW-AVERAGE RISK result.2-4
Low-Average Risk Report
High Risk Report
PROSTOX Standard
Patients with a HIGH RISK result are ~11 times more likely to develop late grade ≥ 2 genitourinary toxicity compared to those with a LOW-AVERAGE RISK result.2,5
Low-Average Risk Report
High Risk Report
PROSTOX
References:
- Weidhaas JB, Marco N, Steinberg ML, et al. Early findings from the GARUDA trial: The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making. J Clin Oncol. 2023;41(16_suppl):5089-5089. doi:https://doi.org/10.1200/jco.2023.41.16_suppl.5089.
- Kishan AU, Marco N, Schulz-Jaavall MB, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiother Oncol. 2022;167:226-232. doi:10.1016/j.radonc.2021.12.040.
- Kishan AU, Marco N, Ma TM, et al. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clin Transl Radiat Oncol. 2023;39doi:10.1016/j.ctro.2023.100594.doi:10.1016/j.ctro.2023.100594.
- Kishan AU, McGreevy K, Valle L, et.al. Validation and derivation of microRNA-based germline signatures predicting radiation toxicity in prostate cancer. Clin Cancer Res. 2025 Jun 13;31(12):2530-2538. doi: 10.1158/1078-0432.CCR-24-3951.
- Kishan AU, McGreevy K, Telesca D, Weidhaas JB. Treatment choices and toxicity outcomes in patients with a high-risk PROSTOX score. Int J Radiat Oncol Biol Phys. 2025;123(1):e615. doi:10.1016/j.ijrobp.2025.06.2894.